| 02-03-2012 07:53 AM CET - Health & Medicine |
|
The latest developments of specific-spectrum, anti-staphyloccal agents using in-vitro, in-vivo and human clinical data
Press release from: SMi Group
(openPR) - Now in its 14th year, Superbugs & Superdrugs is a well established antibacterial event that promises to be the perfect forum for networking and problem solving with senior industry executives from the pharmaceutical sector.
The event will be held on the 5&6 of March at the Copthorne Tara Hotel, London and will be made up of case-study focused presentations, highlighting success stories and lessons to be learnt. With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important and this event will be the perfect opportunity to be kept updated with advances in the antibacterial sector.
Key Benefits of Attending:
• Developments of specific-spectrum, anti-staphyloccal agents using in-vitro, in-vivo and human clinical data
• Evaluating methods to identify beta-lactam synergists and modification to counter bacterial resistance
• Discussing anti(myco) bacterial drug discovery and development in TB research
• Exploring new perspectives on the treatment of CDI
• Updates in anti-fungal and vaccine therapies
• Assess monoclonal antibody prophylaxis as an alternative approach
• Combating antibacterial resistance in developing markets
Key Presentations Include:
Development of vaccines for the prevention of antibiotic-resistant bacterial infections
• Identification of vaccine targets for bacterial pathogens
• Preclinical evaluation of candidate vaccines
• Focus on staphylococcus aurues and Clostridum difficle
Jon Heinrichs, Director, Microbial Vaccines, Merck
Novel LpxC inhibitors for treatment of gram-negative infections
• The SAR of a new series of LpxC inhibitors
• PK and strategies to lower human dose projections
• X-ray crystallographic analysis of bound inhibitors
• MIC90s for multiple gram-negatives
Justin Montgomery, Senior Principal Scientist, Pfizer
For further details and the full programme visit www.smi-online.co.uk/2012superbugs25.asp
Alternatively or Fateja Begum on tel: +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street,
London, SE1 0BS
The event will be held on the 5&6 of March at the Copthorne Tara Hotel, London and will be made up of case-study focused presentations, highlighting success stories and lessons to be learnt. With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important and this event will be the perfect opportunity to be kept updated with advances in the antibacterial sector.
Key Benefits of Attending:
• Developments of specific-spectrum, anti-staphyloccal agents using in-vitro, in-vivo and human clinical data
• Evaluating methods to identify beta-lactam synergists and modification to counter bacterial resistance
• Discussing anti(myco) bacterial drug discovery and development in TB research
• Exploring new perspectives on the treatment of CDI
• Updates in anti-fungal and vaccine therapies
• Assess monoclonal antibody prophylaxis as an alternative approach
• Combating antibacterial resistance in developing markets
Key Presentations Include:
Development of vaccines for the prevention of antibiotic-resistant bacterial infections
• Identification of vaccine targets for bacterial pathogens
• Preclinical evaluation of candidate vaccines
• Focus on staphylococcus aurues and Clostridum difficle
Jon Heinrichs, Director, Microbial Vaccines, Merck
Novel LpxC inhibitors for treatment of gram-negative infections
• The SAR of a new series of LpxC inhibitors
• PK and strategies to lower human dose projections
• X-ray crystallographic analysis of bound inhibitors
• MIC90s for multiple gram-negatives
Justin Montgomery, Senior Principal Scientist, Pfizer
For further details and the full programme visit www.smi-online.co.uk/2012superbugs25.asp
Alternatively or Fateja Begum on tel: +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street,
London, SE1 0BS
News-ID: 209463
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
SMi Group
Comments about openPR
We publish our press releases on openPR.de because we like people who are "open" - just like us.
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH
Frank Obels, CEO, INCONET - Informationssysteme, Communication und Netzwerkberatung GmbH

